Custom Drugs in Spotlight: FDA Info Collection Feedback
Published Date: 2/23/2026
Notice
Summary
The FDA is asking for public feedback on how it collects information about drug compounding, where pharmacists mix medicines just for patients who need them. This helps keep these special medicines safe and effective while making sure patients can still get them. Comments are open until March 25, 2026, so pharmacists and facilities should weigh in soon!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
503A Pharmacy Reporting and Recordkeeping Burden
Pharmacies that compound under section 503A have reporting and recordkeeping duties. FDA estimates 45 respondents with ~197 reports each (8,879 total annual responses) at 0.87 hours per response (7,968 total hours) for 503A reporting, plus 503A recordkeeping estimated at 90 responses at 1 hour each (90 total hours).
Adverse Event Reporting and Recordkeeping
Outsourcing facilities must submit adverse event reports under section 503B(b)(5) in accordance with 21 CFR 310.305(e)(1), generally within 15 calendar days with 15-day follow-ups as needed, and must maintain adverse event records for 10 years. FDA estimates 503B AER reporting covers 55 respondents with 55 total AERs (average 1.10 hours each = 61 hours) and associated recordkeeping estimated at 880 hours (55 respondents × 16 hours). Reports must be submitted electronically using Form FDA 3500A (OMB control number 0910-0291).
503B Outsourcing Facility Reporting Burden
If you operate or register an outsourcing compounding facility under section 503B, you must submit reports identifying the drugs you compound as required by sections 503B(b)(1)–(3). FDA estimates this activity covers about 75 respondents making ~108 reports each (8,111 total annual responses) at an average 0.2 hours per response, totaling 214 hours annually.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2026-03447 — Self-Regulatory Organizations; MIAX Emerald, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 531 To Establish the New Purge Liquidity Taker Event Report
MIAX Emerald is rolling out a new optional report called the Purge Liquidity Taker Report for Market Makers. This update tweaks Exchange Rule 531 to help traders get clearer info on liquidity takers. The change is effective immediately, aiming to boost transparency without extra costs right now.
Next: 2026-03449 — Self-Regulatory Organizations; New York Stock Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change for Amendments to Rule 7.35A and Rule 7.35C
The New York Stock Exchange is updating how it calculates prices during opening and trading halt auctions to make them more accurate. These changes affect traders and market makers who rely on these auctions to set fair prices. The new rules took effect right after filing on February 6, 2026, aiming to improve market fairness without changing fees.